AU2002220822A1 - For amyloid formation inhibitors - Google Patents

For amyloid formation inhibitors

Info

Publication number
AU2002220822A1
AU2002220822A1 AU2002220822A AU2082202A AU2002220822A1 AU 2002220822 A1 AU2002220822 A1 AU 2002220822A1 AU 2002220822 A AU2002220822 A AU 2002220822A AU 2082202 A AU2082202 A AU 2082202A AU 2002220822 A1 AU2002220822 A1 AU 2002220822A1
Authority
AU
Australia
Prior art keywords
amyloid formation
formation inhibitors
inhibitors
amyloid
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220822A
Inventor
Matthew Guy Cottingham
David John Talbutt Vaux
Jan Louis Albert Voskuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptica Ltd
Original Assignee
Synaptica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptica Ltd filed Critical Synaptica Ltd
Publication of AU2002220822A1 publication Critical patent/AU2002220822A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002220822A 2000-11-23 2001-11-23 For amyloid formation inhibitors Abandoned AU2002220822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0028578A GB0028578D0 (en) 2000-11-23 2000-11-23 Screening assays
GB0028578.3 2000-11-23
PCT/GB2001/005189 WO2002042778A2 (en) 2000-11-23 2001-11-23 For amyloid formation inhibitors

Publications (1)

Publication Number Publication Date
AU2002220822A1 true AU2002220822A1 (en) 2002-06-03

Family

ID=9903732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220822A Abandoned AU2002220822A1 (en) 2000-11-23 2001-11-23 For amyloid formation inhibitors

Country Status (3)

Country Link
AU (1) AU2002220822A1 (en)
GB (1) GB0028578D0 (en)
WO (1) WO2002042778A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB201505239D0 (en) * 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody
GB2546773B (en) 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
WO1998037421A1 (en) * 1997-02-19 1998-08-27 Regents Of The University Of Minnesota Aβ DEPOSITION INHIBITOR SCREEN USING SYNTHETIC AMYLOID

Also Published As

Publication number Publication date
WO2002042778A3 (en) 2002-10-17
GB0028578D0 (en) 2001-01-10
WO2002042778A2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2001243517A1 (en) Plug for tubulars
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001269939A1 (en) Methods for eliminating the formation of biofilm
AU2002219555A1 (en) VLA-4 Inhibitors
AU4882101A (en) Mmp-12 inhibitors
AU2001234088A1 (en) TNF-alpha inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2001290685A1 (en) Methods for inhibiting inflammatory disease
AU2001285750A1 (en) Urokinase inhibitors
AU2002230385A1 (en) Peptide deformylase inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU2001236623A1 (en) Hydantoin c-proteinase inhibitors
AU2001244562A1 (en) Neovascularization inhibitors
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU3235100A (en) Prothease inhibitors
AU2001220281A1 (en) Rollerboard for road-skiing